KATIE VIEIRA: Open Payments
NPI 1114471562 · LAFAYETTE, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,329 in 100 payments from 12 companies in 2025. Trend: 2023 $1,936 · 2024 $1,919 · 2025 $2,329
Food & beverage: $2,329
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $618 |
| Gilead Sciences, Inc. | 14 | $335 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $254 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $213 |
| Ardelyx, Inc. | 7 | $202 |
| Janssen Biotech, Inc. | 7 | $150 |
| Regeneron Healthcare Solutions, Inc. | 5 | $145 |
| Madrigal Pharmaceuticals | 3 | $139 |
| Phathom Pharmaceuticals, Inc. | 5 | $107 |
| Lilly USA, LLC | 5 | $92 |
Products named: RINVOQ, XIFAXAN, IBSRELA, DUPIXENT, ENTYVIO, TREMFYA, REZDIFFRA, VOQUEZNA.
Industry payments across CO — which companies pay providers there.
